Addition of Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

To determine the feasibility of adding cabozantinib S-malate (cabozantinib) to standard MAP (high dose methotrexate, doxorubicin hydrochloride [doxorubicin], and cisplatin) chemotherapy in patients with newly diagnosed metastatic osteosarcoma with a resectable primary tumor; To determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival than MAP chemotherapy alone in patients with localized, resectable osteosarcoma; To determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival than MAP chemotherapy alone in patients with metastatic, pelvic and unresectable osteosarcoma.

• Children and Adults 0-40 years of age
• Must have histologic diagnosis of newly diagnosed high-grade osteosarcoma
• Must have a body surface area of > 0.8 m^2 at the time of enrollment

• Methotrexate, doxorubicin, and cisplatin given intravenously with or without cabozantinib given orally
• Bone Scan
• X-ray
• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Blood samples